Aakash Desai/LinkedIn
Jul 23, 2025, 18:48
Aakash Desai: NSCLC – 85% of Lung Cancers, Sales Projected to Grow from $31.7B to $56.1B by 2032
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn about a recent paper by Charlotte B. Jago and Rachel M. Webster published in Nature:
“Nature Portfolio Reviews Drug Discovery’s latest From the Analyst’s Couch dives deep into the NSCLC market.
- Market: NSCLC ≈ 85% of lung cancers; sales projected to grow from ~US$31.7B (2024) to ~US$56.1B by 2032.
- Growth drivers: Expansion into adjuvant/neoadjuvant settings, rising biomarker testing, and fast-growing China/emerging markets.
- Biology/Biomarkers: EGFR, ALK, KRAS G12C, HER2, MET, RET, etc.; ctDNA/MRD assays moving toward routine use.
- Therapeutics: Next‑gen TKIs, ADCs, bispecifics, PROTACs; IO combos beyond PD‑1/L1 (e.g., TIGIT, LAG‑3).
- Unmet needs: Post‑targeted and IO resistance, IO‑refractory/low PD‑L1 disease, brain mets, and equitable access to testing.
- Trials/Regulation: Platform/adaptive designs; perioperative endpoints (pCR, EFS) under scrutiny; tighter post‑marketing requirements.
- Access/Value: Payers demanding differentiation and outcomes data amid crowded classes.”
Title: The non-small-cell lung cancer drug market
More posts featuring Aakash Desai.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 23, 2025, 18:11
Jul 23, 2025, 17:13
Jul 23, 2025, 16:56